FAQ

FAQ

*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

References

  • Jones M.L., Martoni,C.J., Ganopolsky,J.G., Sulemankhil,I., & Prakash,S. Improvement of gastrointestinal health status in subjects consuming L. reuteri NCIMB 30242 capsules: a post hoc analysis of a randomized controlled trial. Expert Opinion on Biological Therapy (accepted), (2013).
  • Jones,M.L., Martoni,C.J., & Prakash,S. Letter to the editor regarding the report of Duboc et al: connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease. Gut(2012).
  • Jones,M.L., Martoni,C.J., & Prakash,S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur. J Clin. Nutr. 66, 1234-1241 (2012).
  • Campbell,J.M., Fahey,G.C., Jr., & Wolf,B.W. Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J Nutr. 127, 130-136 (1997).
  • Environ International Corporation. Short-Chain Fructooligosaccharide GRAS Notice. GRN000044. 2000. Ref Type: Report
  • Macfarlane,G.T. & Cummings,J.H. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? West J Med 171, 187-191 (1999).
  • Oli,M.W., Petschow,B.W., & Buddington,R.K. Evaluation of fructooligosaccharide supplementation of oral electrolyte solutions for treatment of diarrhea: recovery of the intestinal bacteria. Dig. Dis Sci. 43, 138-147 (1998).
  • Cherbut,C., Michel,C., & Lecannu,G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J Nutr. 133, 21-27 (2003).
  • Bouhnik,Y. et al. The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am. J Clin. Nutr. 80, 1658-1664 (2004).
  • Bouhnik,Y., Raskine,L., Simoneau,G., Paineau,D., & Bornet,F. The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: a dose-response relationship study in healthy humans. Nutr. J 5, 8 (2006).
  • Jones,M.L., Martoni,C.J., Parent,M., & Prakash,S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br. J. Nutr.1-9 (2011).
  • Jones,M.L., Martoni,C.J., & Prakash,S. Oral Supplementation With Probiotic L. reuteri NCIMB 30242 Increases Mean Circulating 25-Hydroxyvitamin D: A Post Hoc Analysis of a Randomized Controlled Trial. J Clin. Endocrinol. Metab 98, 2944-2951 (2013).
  • Yoon,S.S. & Sun,J. Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. Gastroenterol. Res. Pract. 2011, 971938 (2011).
  • Sayin,S.I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17, 225-235 (2013).
  • Swann,J.R. et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl. Acad. Sci. U. S. A 108 Suppl 1, 4523-4530 (2011).
  • Inagaki,T. et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U. S. A 103, 3920-3925 (2006).
  • Hofmann,A.F. & Eckmann,L. How bile acids confer gut mucosal protection against bacteria. Proc. Natl. Acad. Sci. U. S. A 103, 4333-4334 (2006).
  • Duboc,H. et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut(2012).
  • Duboc,H. et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 24, 513-517 (2012).
  • Ogilvie,L.A. & Jones,B.V. Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease? Gut 61, 1642-1643 (2012).
  • Clemente,J.C., Ursell,L.K., Parfrey,L.W., & Knight,R. The impact of the gut microbiota on human health: an integrative view. Cell 148, 1258-1270 (2012).
  • Blaser,M.J. & Falkow,S. What are the consequences of the disappearing human microbiota? Nat. Rev. Microbiol 7, 887-894 (2009).
  • Dominguez-Bello,M.G. et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. U. S. A 107, 11971-11975 (2010).
  • The Human Microbiome Project. Baylor College of Medicine . 2013. 8-8-2013. Ref Type: Electronic Citation
  • Palmer,C., Bik,E.M., DiGiulio,D.B., Relman,D.A., & Brown,P.O. Development of the human infant intestinal microbiota. PLoS. Biol. 5, e177 (2007).
  • Turnbaugh,P.J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031 (2006).
  • Brestoff,J.R. & Artis,D. Commensal bacteria at the interface of host metabolism and the immune system. Nat. Immunol. 14, 676-684 (2013).
  • Marchesi,J.R. et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome. Res. 6, 546-551 (2007).
  • Holmes,E. et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453, 396-400 (2008).
  • Koeth,R.A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med 19, 576-585 (2013).
  • Tang,W.H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J Med 368, 1575-1584 (2013).
  • Ley,R.E., Turnbaugh,P.J., Klein,S., & Gordon,J.I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023 (2006).
  • Walter,J. & Ley,R. The human gut microbiome: ecology and recent evolutionary changes. Annu. Rev. Microbiol 65, 411-429 (2011).
  • Wu,G.D. et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334, 105-108 (2011).
  • Jones,M.L., Martoni,C.J., Tamber,S., Parent,M., & Prakash,S. Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: A randomized, placebo-controlled, double-blind study. Food Chem Toxicol. 2012. Ref Type: In Press
  • Jones,M.L., Martoni,C.J., Di,P.E., Simon,R.R., & Prakash,S. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial. Regul. Toxicol. Pharmacol. 63, 313-320 (2012).
  • Micropharma Limited. Lactobacillus reuteri NCIMB 30242 GRAS Notice. GRN000440. 2012. Ref Type: Report